The Journal of Immunology, Vol 150, Issue 3 1055-1064, Copyright © 1993 by American Association of Immunologists

ARTICLES

Soluble complement receptor type 1 prevents human complement-mediated damage of the rabbit isolated heart

JW Homeister, PS Satoh, KS Kilgore and BR Lucchesi
University of Michigan Medical School, Department of Pharmacology, Ann Arbor 48109-0626.

The purpose of this study was to determine if recombinant human soluble CR1 (sCR1) could prevent tissue damage associated with the activation of human complement. Directly mediated human complement-dependent myocardial injury was induced in the rabbit isolated heart perfused with a Krebs-Henseleit buffer containing 6% human plasma. There were three study groups: 1) 6% heat-inactivated human plasma (control); 2) 6% normal human plasma (NHP); or 3) 6% normal human plasma + 20 nM sCR1 (NHP + sCR1). Recorded functional parameters of the control group remained stable throughout the duration of the 70-min protocol. Complement activation in hearts perfused with 6% NHP increased the diastolic pressure; decreased developed pressure; and increased coronary perfusion pressure. These alterations were accompanied by a decrease in the maximum positive and negative dP/dt. Complement activation also increased cardiac muscle lymphatic fluid flow rate. The changes were greatest between 20 and 40 min, but persisted for the duration of the protocol. sCR1 (20 nM) in the perfusate containing 6% NHP prevented the complement-mediated alterations in the systolic, developed, and coronary perfusion pressures. sCR1 prevented the decrement in the positive and negative dP/dt, and the increase in the lymphatic fluid flow rate. Values for each of these parameters in hearts perfused with 6% NHP + sCR1 were not altered from those of controls at any time point in the protocol. Ultrastructural changes were present in tissues perfused with 6% NHP along with immunohistochemical evidence for presence of the terminal C5b-9 complex. sCR1 prevented the ultrastructural changes and the formation of the terminal complex. sCR1 offers significant protection against the cytolytic effects resulting from activation of the human complement system.

This article has been cited by other articles:

				V. Ramaglia, R. Wolterman, M. de Kok, M. A. Vigar, I. Wagenaar-Bos, R. H. M. King, B. P. Morgan, and F. Baas Soluble Complement Receptor 1 Protects the Peripheral Nerve from Early Axon Loss after Injury Am. J. Pathol., April 1, 2008; 172(4): 1043 - 1052. [Abstract] [Full Text] [PDF]

				Y. Banz, O. M. Hess, S. C. Robson, E. Csizmadia, D. Mettler, P. Meier, A. Haeberli, S. Shaw, R. A. Smith, and R. Rieben Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1 Cardiovasc Res, December 1, 2007; 76(3): 482 - 493. [Abstract] [Full Text] [PDF]

				P. J. Chai, R. Nassar, A. E. Oakeley, D. M. Craig, G. Quick Jr, J. Jaggers, S. P. Sanders, R. M. Ungerleider, and P. A. W. Anderson Soluble Complement Receptor-1 Protects Heart, Lung, and Cardiac Myofilament Function From Cardiopulmonary Bypass Damage Circulation, February 8, 2000; 101(5): 541 - 546. [Abstract] [Full Text] [PDF]

				A. R. ROSENKRANZ, G. F. KÖRMÖCZI, F. THALHAMMER, E. J. MENZEL, W. H. HÖRL, G. MAYER, and G. J. ZLABINGER Novel C5-Dependent Mechanism of Neutrophil Stimulation by Bioincompatible Dialyzer Membranes J. Am. Soc. Nephrol., January 1, 1999; 10(1): 128 - 135. [Abstract] [Full Text]

				K. S. Kilgore, K. B. Naylor, E. J. Tanhehco, J. L. Park, E. A. Booth, R. A. Washington, and B. R. Lucchesi The Semisynthetic Polysaccharide Pentosan Polysulfate Prevents Complement-Mediated Myocardial Injury in the Rabbit Perfused Heart J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 987 - 994. [Abstract] [Full Text]

				H. L. Lazar, T. Hamasaki, Y. Bao, S. Rivers, S. A. Bernard, and R. J. Shemin Soluble Complement Receptor Type I Limits Damage During Revascularization of Ischemic Myocardium Ann. Thorac. Surg., April 1, 1998; 65(4): 973 - 977. [Abstract] [Full Text] [PDF]

				S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]

				G. L. Stahl, W. R. Reenstra, and G. Frendl Complement-Mediated Loss of Endothelium-Dependent Relaxation of Porcine Coronary Arteries : Role of the Terminal Membrane Attack Complex Circ. Res., April 1, 1995; 76(4): 575 - 583. [Abstract] [Full Text]